Multicenter clinical study on the efficacy and safety with extensive and repeated injections of cultured (human) autologous hair follicle dermal sheath cup cells on male and female pattern hair loss

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTb032200148

Enrollment

Registered

2020-10-13

Start date

2020-12-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

male and female pattern hair loss

Interventions

1. blood sampling from the subjects. 2. In study subjects, skin sampling from the occipital scalp after local anesthesia and sutures & removals of stiches at the site of sampling will be performed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female of 20 year old or more with in good health having pattern hair loss involving the vertex area of the scalp. 2. Male subjects with pattern hair loss characterized as type III vertex to type VI on the Norwood Scale, or equivalent type. Female subjects with pattern hair loss characterized as type 3 to type 6 of the Shiseido Scale. 3. Subjects with willingness to provide written informed consent for participation in the study, to attend all study visits and to complete all procedures required by this protocol. 4. Subjects with willingness to forego the use quasi drug or medical products for hair growth throughout the course of the study.

Exclusion criteria

Exclusion criteria: 1. Use of any product (medication or otherwise) which interferes with the hair growth cycle. 2. Any systemic medical treatment or quasi drug for hair growth within six months prior to obtaining the Informed Consent. Or those who underwent hair loss therapies by LED and/or low power output of raiser radiation within six months prior to obtaining the Informed Consent. 3. Presence of any medical condition that influences the hair growth cycle. 4. Infection with viruses such as HBV, HCV, HIV, adult T-cell leukemia, parvovirus or VDS has been confirmed by virological examination and syphilis testing carried out at the time of the screening.

Design outcomes

Primary

Measure	Time frame
Based on the global photo assessment, photos will have to be taken at 12 months medications, and will be employed as a primary endpoint. These photos taken following injections of S-DSC will have to be analyzed.	—

Secondary

Measure	Time frame
Quantitative analysis by Phototrichogram (hair density etc.)	—

Countries

Japan

Contacts

Public ContactKazutoshi Harada

Tokyo Medical University Hospital

kharada@tokyo-med.ac.jp+81-3-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026